HSBC Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

HSBC Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-400	Closed	-$73K	–	3254
2021 Q2	$73K	Hold	400	–	–	﹤0.01%	2872
2021 Q1	$61K	Buy	+400	New	+$61.9K	﹤0.01%	2657
2020 Q1	–	Sell	-12,500	Closed	-$1.35M	–	3140
2019 Q4	$1.35M	Sell	12,500 -7,300	-37%	-$781K	﹤0.01%	1676
2019 Q3	$1.94M	Sell	19,800 -35,000	-64%	-$3.95M	﹤0.01%	1622
2019 Q2	$7.18M	Buy	54,800 +38,800	+243%	+$5M	0.01%	991
2019 Q1	$2.16M	Sell	16,000 -21,300	-57%	-$2.65M	﹤0.01%	1476
2018 Q4	$3.63M	Buy	37,300 +19,000	+104%	+$2.25M	0.01%	1244
2018 Q3	$2.54M	Buy	18,300 +16,000	+696%	+$2.01M	﹤0.01%	1382
2018 Q2	$286K	Buy	2,300 +2,000	+667%	+$234K	﹤0.01%	2301
2018 Q1	$33K	Buy	+300	New	+$35.9K	﹤0.01%	2517
2017 Q4	–	Sell	-300	Closed	-$42K	–	2462
2017 Q3	$42K	Buy	+300	New	+$40.8K	﹤0.01%	2261
2015 Q3	–	Sell	-846	Closed	-$153K	–	2226
2015 Q2	$153K	Buy	+846	New	+$146K	﹤0.01%	1873
2013 Q3	–	Sell	-46,555	Closed	-$4.29M	–	1805
2013 Q2	$4.29M	Buy	+46,555	New	+$4.49M	0.01%	731

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

HSBC Holdings's ALXN Position: Q3 2021 in Review

HSBC Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 454,149 shares — an estimated $83.5M sold.

HSBC Holdings first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $97.6M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

HSBC Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
HSBC Holdings sold 454,149 Alexion Pharmaceuticals shares in Q3 2021, an estimated $83.5M.
HSBC Holdings first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
HSBC Holdings's Alexion Pharmaceuticals position peaked at $97.6M in Q1 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on HSBC Holdings's 13F filing for Q3 2021, filed 12 Nov 2021.